Evotec stock at EUR 2.81 ahead of the Xetra open: drug discovery group falls 1.06 percent
Published on 10/23/2026 at 09:00 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSBusiness model and market context
- Evotec's model links partner research with milestone and license revenue.
- Germany's DAX frames the October 23, 2026 market context.
- Evotec stock trades pre-market at EUR 2.81 at 8:59 a.m. CEST at Lang & Schwarz on October 23, 2026, 1.06 percent below the Xetra close of October 22, 2026.
Evotec uses data science, artificial intelligence and partner collaborations to develop medicines, according to its Investor Relations information. Evotec stock trades pre-market at EUR 2.81 at 8:59 a.m. CEST at Lang & Schwarz on October 23, 2026, 1.06 percent below the Xetra close of October 22, 2026 (EUR 2.84).
Ahead of the Xetra open
The indication is EUR 0.03 below the reference level. The further course from the Xetra open at 9:00 a.m. CEST is shown by the continuously updated real-time quote of Evotec stock.
How Evotec earns revenue
Revenue is generated through collaborations that can include milestones, licenses and success-linked revenue shares, while Just–Evotec Biologics provides contract development and manufacturing services, as described by Evotec. The German market context is represented by the DAX on October 23, 2026. No company-specific event due before the Xetra open is evidenced in the cited material.
Market context: Market report DAX.
